Compare · CDIO vs ORKA
CDIO vs ORKA
Side-by-side comparison of Cardio Diagnostics Holdings Inc. (CDIO) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDIO and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $5.56B, about 1211.7x CDIO ($4.6M).
- Over the past year, CDIO is down 64.4% and ORKA is up 548.8% - ORKA leads by 613.2 points.
- CDIO has been more active in the news (5 items in the past 4 weeks vs 4 for ORKA).
- ORKA has more recent analyst coverage (11 ratings vs 0 for CDIO).
PerformanceCDIO-64.40%ORKA+548.77%
2025-07-25+0.00%2026-07-24
- Company
- Cardio Diagnostics Holdings Inc.
- Oruka Therapeutics Inc.
- Price
- $1.57-2.48%
- $92.13+0.21%
- Market cap
- $4.6M
- $5.56B
- 1M return
- -22.28%
- +12.13%
- 1Y return
- -64.40%
- +548.77%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 5
- 4
- Recent ratings
- 0
- 11
Latest CDIO
- SEC Form PRE 14A filed by Cardio Diagnostics Holdings Inc.
- SEC Form 4 filed by Director Fung Peter K
- SEC Form 4 filed by Director Betts Wendy J
- SEC Form 4 filed by Director Intrater James
- SEC Form 4 filed by Director Burton Paul Frederick
- Atlas Healthcare Physicians to Cover Cardio Diagnostics’ Precision Cardiovascular Medicine Tests Across Its Network
- Cardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in June
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Meesha Dogan, CEO of Cardio Diagnostics Holdings Inc.
- SEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.
- IBN Initiates Coverage of Cardio Diagnostics Holdings Inc.
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $603,938 worth of shares (7,000 units at $86.28) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,999 shares at a strike of $15.69 and sold $846,180 worth of shares (9,999 units at $84.63) as part of a pre-agreed trading plan (SEC Form 4)
- Director Fairmount Funds Management Llc converted options into 3,553,410 shares and sold $300,014,406 worth of shares (3,553,410 units at $84.43) (SEC Form 4)
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $472,079 worth of shares (5,000 units at $94.42) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes
- Chief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes
- Chief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)
- General Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)